Investor Relations



Scroll-Down-white

About Awakn

Awakn Life Sciences is a biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction.

Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally. 

Price: 0 AWKN (NEO)

PRESS RELEASES      |      INVESTOR DECK      |      FINANCIALS

Press Releases

Awakn Establishes Preclinical And Clinical Expert Advisory Boards

07.07.2021.

Awakn Establishes Preclinical And Clinical Expert Advisory Boards

READ MORE

Awakn-banner-june-2021-01

28.06.2021.

Awakn Files Patent Applications For 2 New Chemical Entities To Treat Addiction

READ MORE

Corporate Presentation

Asset-2

DOWNLOAD

CP_Awakn

Financials

Asset-2

VISIT SEDAR

thumb-1

Newsletter Sign Up 

Enquiries

Investor Enquiries:

KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
awakn@KCSA.com

Media Enquiries:

AMERICA AND CANADA:
KCSA Strategic Communications 
Anne Donohoe
adonohoe@KCSA.com

REST OF WORLD:
ROAD Communications
Paul Jarman / Anna Ramsey
awakn@roadcommunications.co.uk

Sign Up for Newsletter:

MAIN OFFICE
Suite 200, 366 Bay St,
Toronto, Ontario, M5H 4B2, Canada

UK OFFICE
1 Regent Street,
Bristol, BS8 4HW, United Kingdom

© 2021 Awakn Life Sciences Corp      |      Privacy Policy      |      Appropriate Use Policy